Cérences, France (October 22, 2024) Particles for Humanity, in partnership with LIS by Lesaffre, successfully manufactured commercial scale batches of PFH-VAP, the company’s lead product. PFH-VAP was designed to improve vitamin A stability for use in large scale food fortification, an intervention proven to address micronutrient deficiencies at scale.

Chicago, IL (July 24, 2024) Particles for Humanity was selected to present a poster at the American Society for Nutrition 2024 Conference in Chicago, Illinois. The poster showcased the importance of manufacturing process conditions on the stability of PFH-VAP, the company’s lead vitamin A product.

Cambridge, MA (April 2nd, 2024). Particles for Humanity has completed a study of the taste and smell of bouillon cubes containing the company’s lead product, a stable form of vitamin A, called PFH-VAP.

March 21, 2024. Last week, the Corporate Outreach Committee of Brown Biomedical Engineering Board (BMEB) sponsored a Roles in Biotech Panel with speakers from mission-oriented biotech start-up, Particles for Humanity (PFH).

Particles for Humanity has assembled an advisory board of global leaders to guide the company as it approaches commercialization of its lead product, PFH-VAP, and as it expands its research and development pipeline to include new applications for PFH-VAP.

Particles for Humanity has received approval from the Institutional Review Board (IRB) at the University of Wisconsin-Madison in the United States to begin a human absorption study of PFH-VAP, a stable form of vitamin A.

Showcasing a new product to improve the impact of interventions for vitamin A deficiency in low and lower-middle income countries (LMICs).

Particles for Humanity has secured funding from King Philanthropies and the Mulago Foundation to test the absorption of vitamin A from PFH-VAP, a stable form of vitamin A palmitate for large-scale food fortification (LSFF) in humans.

Particles for Humanity has raised $10 million in grant funding to prepare its stable form of vitamin A (PFH-VAP) for adoption by national wheat flour fortification programs.

Cambridge, MA (December 13, 2022). Particles for Humanity attended the National Fortification Alliance meeting in Lagos, Nigeria at the invitation of the Director General of the National Agency for Food and Drug Administration and Control (NAFDAC), which is responsible for registering new products and ensuring food fortification mandate compliance.

Particles for Humanity transforms medical tech for low-resource settings.

Encapsulated vitamin A product significantly outperforms commercial products.

Particles for Humanity, a life sciences company transforming early-stage technologies into products for people in low-resource settings, has appointed Dr. Amadou Alpha Sall and Andrew Jack to its Board of Directors.

Particles for Humanity has raised $4 million from the Bill & Melinda Gates Foundation, King Philanthropies, and the Mulago Foundation to address vitamin A deficiency in low-resource settings.

Codex Alimentarius Commission has approved the addition of Basic Methacrylate Copolymer (BMC, INS 1205) to the General Standards for Food Additives (GSFA).

Watch our Senior Scientist, Kadryn Kadasia, present on our progress and the huge potential of this technology at the Annual Rabies in the Americas Conference (RITA).

Particles for Humanity, a life sciences company transforming early-stage technologies into products for people in low-resource settings, has appointed Mark Kessel as Chairman of its Board of Directors.

Each year, we at BostInno look back at our coverage from the last 12 months and try to identify the startups that are on the precipice of something big.

Particles for Humanity has received $5 million from the Bill & Melinda Gates Foundation to develop a product that has potential to help millions of people who suffer serious medical consequences from malnutrition.

View our presentation for the 37th Annual JP Morgan Healthcare Conference.